See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Future Outlooks and Next Steps in Later R/R MM

Summary by oncnursingnews.com
Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient quality of life, while emphasizing that temporary treatment holds due to adverse effects are manageable, and ongoing research is vital to address unmet needs and advance multiple myeloma care.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

oncnursingnews.comoncnursingnews.com

Future Outlooks and Next Steps in Later R/R MM

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient quality of life, while emphasizing that temporary treatment holds due to adverse effects are manageable, and ongoing research is vital to address unmet needs and advance multiple myeloma care.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

oncnursingnews.com broke the news in on Wednesday, August 6, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

News
For You
SearchBlindspotLocal